Canlyniadau Chwilio - Hakim Mahammedi

  • Dangos 1 - 11 canlyniadau o 11
Mireinio'r Canlyniadau
  1. 1
    Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer

    Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer gan Judith Passildas, Jean‐Christophe Eymard, Mélanie Pouget, Fabrice Kwiatkowski, Isabelle Van Praagh, L. Savareux, Marc Atger, Xavier Durando, Catherine Abrial, Damien Richard, Angeline Ginzac, Émilie Thivat, Brigitte Monange, P. Chollet, Hakim Mahammedi

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial

    Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial gan Padmanee Sharma, Russell K. Pachynski, Vivek Narayan, Aude Fléchon, Gwénaëlle Gravis, Matthew D. Galsky, Hakim Mahammedi, Akash Patnaik, Sumit K. Subudhi, Marika Ciprotti, Burçin Şimşek, Abdel Saci, Yanhua Hu, G. Celine Han, Karim Fizazi

    Cyhoeddwyd 2020
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography

    The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography gan Yohann Loriot, Matthieu Texier, Stéphane Culine, Aude Fléchon, Antoine Thiery-Vuillemin, Gwénaëlle Gravis, L. Geoffrois, Christine Chevreau, Marine Gross‐Goupil, Philippe Barthélémy, Emmanuelle Bompas, Hakim Mahammedi, Brigitte Laguerre, Sophie Abadie Lacourtoisie, Carole Hélissey, Sylvain Ladoire, Christine Abraham, Christophe Massard, Séréna Grimaldi, Karim Fizazi

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

    Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT... gan Sumanta K. Pal, Laurence Albigès, Piotr Tomczak, Cristina Suárez, Martin H. Voss, Guillermo de Velasco, Jad Chahoud, Anastasia Mochalova, Giuseppe Procopio, Hakim Mahammedi, Friedemann Zengerling, Chan Kim, Takahiro Osawa, Martín Ángel, Suyasha Gupta, Omara Khan, Guillaume Bergthold, Bo Liu, Melania Kalaitzidou, Mahrukh Huseni, Christian Scheffold, Thomas Powles, Toni K. Choueiri

    Cyhoeddwyd 2023
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study

    Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study gan Ronan Flippot, Cécile Dalban, Brigitte Laguerre, Delphine Borchiellini, Gwénaëlle Gravis, Sylvie Négrier, Christine Chevreau, Florence Joly, Lionnel Geoffrois, Sylvain Ladoire, Hakim Mahammedi, Frédéric Rolland, Marine Gross‐Goupil, Élise Deluche, Frank Priou, Mathieu Laramas, Philippe Barthélémy, Bérengère Narciso, Nadine Houédé, Stéphane Culine, Stéphane Oudard, Marina Chenot, Florence Tantot, Sylvie Chabaud, Bernard Escudier, Laurence Albigès

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC)

    579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC) gan Daniel P. Petrylak, Jose Luis Pérez‐Gracia, Louis Lacombe, Diogo Assed Bastos, Hakim Mahammedi, Edmond M. Kwan, Stefanie Zschäbitz, Andrew J. Armstrong, Russell K. Pachynski, Jeffrey C. Goh, Mauricio Burotto, Gwénaëlle Gravis, Steve McCune, Juan Carlos Vázquez Limón, Margitta Retz, Fred Saad, Neha P. Amin, Jianqing Li, Keziban Ünsal-Kaçmaz, Karim Fizazi

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

    Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multic... gan Eugene D. Kwon, Charles G. Drake, H. I. Scher, Karim Fizazi, Alberto Bossi, Alfons J.M. van den Eertwegh, Michael Krainer, Nadine Houédé, Ricardo Vieira Santos, Hakim Mahammedi, Siobhan Ng, Michele Maio, Fábio Franke, Santhanam Sundar, Neeraj Agarwal, Andries M. Bergman, Tudor‐Eliade Ciuleanu, Ernesto Korbenfeld, Lisa Sengeløv, Steinbjørn Hansen, C. Logothetis, Tomasz M. Beer, M. Brent McHenry, Paul Gagnier, David Liu, Winald R. Gerritsen

    Cyhoeddwyd 2014
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors

    Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long... gan Karim Fizazi, Charles G. Drake, Tomasz M. Beer, Eugene D. Kwon, Howard I. Scher, Winald R. Gerritsen, Alberto Bossi, Alfons J.M. van den Eertwegh, Michael Krainer, Nadine Houédé, Ricardo Vieira Santos, Hakim Mahammedi, Siobhan Ng, Riccardo Danielli, Fábio Franke, Santhanam Sundar, Neeraj Agarwal, Andries M. Bergman, Tudor‐Eliade Ciuleanu, Ernesto Korbenfeld, Lisa Sengeløv, Steinbjørn Hansen, M. Brent McHenry, Allen Chen, Christopher J. Logothetis

    Cyhoeddwyd 2020
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS

    Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS gan Neal D. Shore, Christian Gratzke, Susan Feyerabend, Patrick Werbrouck, Joan Carles, Egils Vjaters, Teuvo L.J. Tammela, David Morris, Jeanny B. Aragon‐Ching, Raoul S. Concepcion, Urban Emmenegger, Neil Fleshner, Markus Grabbert, V. Lietuvietis, Hakim Mahammedi, Francisco Cruz, Adriano Augusto Peclat de Paula, Christopher Pieczonka, Antti Rannikko, Martin Eduardo Richardet, Glauco Costa Silveira, Iris Kuss, Marie‐Aude Le Berre, Frank Verholen, Toni Sarapohja, Matthew Ryan Smith, Karim Fizazi

    Cyhoeddwyd 2024
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

    Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial gan Karim Fizazi, Margitta Retz, Daniel P. Petrylak, Jeffrey C. Goh, Jose Luis Pérez‐Gracia, Louis Lacombe, Stefanie Zschäbitz, Mauricio Burotto, Hakim Mahammedi, Gwénaëlle Gravis, Diogo Assed Bastos, Steven McCune, Juan Carlos Vázquez Limón, Edmond M. Kwan, Daniel Castellano, Aude Fléchon, Fred Saad, Marc‐Oliver Grimm, David R. Shaffer, Andrew J. Armstrong, Prabhu Bhagavatheeswaran, Neha P. Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Jun Li, Andrea Loehr, Russell K. Pachynski

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

    Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer gan Kim N., Dana E. Rathkopf, Matthew R. Smith, Eleni Efstathiou, Gerhardt Attard, David Olmos, Ji Youl Lee, Eric J. Small, Andrea Juliana Gomes, Guilhem Roubaud, Marniza Saad, Bogdan Żurawski, V.S. Sakalo, Gary Mason, Peter Francis, George Wang, Daphne Wu, Brooke Diorio, Angela Lopez‐Gitlitz, Shahneen Sandhu, María Alejandra Álvarez, Gabriela Gatica, Martín Greco, Ernesto Korbenfeld, Esteban Metrebián, Jorge Salinas, Alejandro Salvatierra, Marcelo Tatangelo, Tom Ferguson, Howard Gurney, Elizabeth Hovey, Anthony M. Joshua, Matos Marco, Gavin Marx, Michelle Morris, Siobhan Ng, David Pook, Shahneen Sandhu, Ali Tafreshi, Thean Hsiang Tan, Tsvetanka Tosheva, Livia Andrade, Felipe Melo Cruz, Luiza Dib Batista Bugiato Faria, J. M. L. Figueiredo, Fábio Franke, Andrea Juliana Gomes, Ariel Galapo Kann, Celio Kussumoto, Suelen Patrícia dos Santos Martins, André M. Murad, Hélio Pinczowski, Giovani Thomaz Pioner, Luís Ferreira Pires, Daniel D’Almeida Preto, Gisele Marinho dos Santos, Eduardo Silva, Jamile Silva, Luciano de Souza Viana, Karina Vianna, Adriano Augusto Peclat de Paula, Zhiwen Chen, Kim Chi, Urban Emmenegger, Neil Fleshner, Sunil Parimi, Fred Saad, Francisco Vera-Badillo, Hongqian Guo, Hong Luo, Lulin Ma, Mingxing Qui, Wei Xue, Yong-Lian Guo, Lei Li, Jinxian Pu, Song Zheng, Qing Zou, Miloš Broďák, Milan Hora, Vladimír Šámal, Vladimír Študent, J Vaňásek, Emmanuelle Bompas, Philippe Barthélémy, Delphine Borchiellini, Aude Fléchon, Hakim Mahammedi, Guilhem Roubaud, Antoine Thiery-Vuillemin, Diégo Tosi, Dominique Spaëth, Carole Hélissey, Martin Boegemann, Susan Feyerabend, Eva Hellmis, Martin Schostak, Gerhardt Attard, Anna Lydon, Ian Sayers

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: